NM_000268.4(NF2):c.1000A>G (p.Met334Val) AND Neurofibromatosis, type 2

Clinical significance:Uncertain significance (Last evaluated: May 22, 2017)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:

Allele description [Variation Report for NM_000268.4(NF2):c.1000A>G (p.Met334Val)]

NM_000268.4(NF2):c.1000A>G (p.Met334Val)

NF2:NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_000268.4(NF2):c.1000A>G (p.Met334Val)
  • NC_000022.11:g.29671826A>G
  • NG_009057.1:g.73271A>G
  • NM_000268.4:c.1000A>GMANE SELECT
  • NM_016418.5:c.1000A>G
  • NM_181825.3:c.1000A>G
  • NM_181828.3:c.874A>G
  • NM_181829.3:c.877A>G
  • NM_181830.3:c.751A>G
  • NM_181831.3:c.751A>G
  • NM_181832.3:c.1000A>G
  • NM_181833.3:c.448-22926A>G
  • NP_000259.1:p.Met334Val
  • NP_000259.1:p.Met334Val
  • NP_057502.2:p.Met334Val
  • NP_861546.1:p.Met334Val
  • NP_861966.1:p.Met292Val
  • NP_861967.1:p.Met293Val
  • NP_861968.1:p.Met251Val
  • NP_861969.1:p.Met251Val
  • NP_861970.1:p.Met334Val
  • LRG_511t1:c.1000A>G
  • LRG_511t2:c.1000A>G
  • LRG_511:g.73271A>G
  • LRG_511p1:p.Met334Val
  • LRG_511p2:p.Met334Val
  • NC_000022.10:g.30067815A>G
  • NM_000268.3:c.1000A>G
  • NR_156186.2:n.1482A>G
Protein change:
dbSNP: rs1556000094
NCBI 1000 Genomes Browser:
Molecular consequence:
  • NM_181833.3:c.448-22926A>G - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000268.4:c.1000A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_016418.5:c.1000A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181825.3:c.1000A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181828.3:c.874A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181829.3:c.877A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181830.3:c.751A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181831.3:c.751A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_181832.3:c.1000A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NR_156186.2:n.1482A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]


Neurofibromatosis, type 2 (NF2)
NF 2; Neurofibromatosis central type; Acoustic schwannomas bilateral; See all synonyms [MedGen]
MONDO: MONDO:0007039; MedGen: C0027832; Orphanet: 637; OMIM: 101000

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV000628840Invitaecriteria provided, single submitter
Uncertain significance
(May 22, 2017)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing



Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]

Details of each submission

From Invitae, SCV000628840.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)


This sequence change replaces methionine with valine at codon 334 of the NF2 protein (p.Met334Val). The methionine residue is moderately conserved and there is a small physicochemical difference between methionine and valine. This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a NF2-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may alter RNA splicing, but this prediction has not been confirmed by published transcriptional studies. In summary, this variant is a novel missense change with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Dec 4, 2021

Support Center